Drug-eluting stents (DES) became available for the treatment of atherosclerotic coronary heart disease about five years ago. The polymer coatings used in the first-generation DES (Cypher™ and Taxus™) were non-biodegradable. Virmani et al. studied autopsy patients and suggested that late stent thrombosis post-DES implantation might be caused by the polymer. 1 Recently, using a hierarchical classification of stent thrombosis, Mauri et al. reported a significantly higher incidence of definite or probable stent thrombosis events in the DES group than in the bare-metal stent (BMS) group during a four-year follow-up. 2 Nowadays, the consensus is to extend clopidogrel usage for a minimum of 12 months (perhaps longer in patients post-DES implantation) to prevent stent thrombosis. However, 
